Please visit Klaria´s Swedish website for recent press releases.
26 October 2018
Klaria signs agreement for EU grant worth ca. 21 MSEK to take migraine product to market
Klaria Pharma Holding AB (publ) announces that the company has finalized and signed the agreement for the grant of 21 MSEK in total from the EU Horizon 2020 program. The grant will, as announced earlier, be used to finalize the development and commerzialisation of KL-00119, the company’s leading candidate for treatment of acute migraine-related pain.
09 August 2017
Klaria signs exclusive development, license and supply agreement with Purdue Pharma (Canada) for acute treatment of opioid overdose (KL-00514)
Klaria AB and Purdue Pharma (Canada) today announce they have entered into exclusive development and license and supply agreements for KL-00514 (Naloxone Buccal Film). KL-00514 is a developmental stage formulation of naloxone intended for acute treatment of intentional or accidental opioid overdose designed to give a rapid and reliable response in patients while providing a compact dosage form that could be distributed widely to patients, caregivers and emergency personnel.
04 November 2015
Another large market patent protected for Klaria’s products
Klaria’s drug delivery technology receives patent in Mexico.
29 October 2015
One step closer to a new preparation for the treatment of migraine
- Klaria´s first product ready for clinical evaluation - Partners have now been contracted The first drug candidate from Klaria Pharma Holding AB (Klaria), KL-00119, intended as a superior product for treating migraine, is now ready for clinical testing. As an important step in preparation for clinical testing, contracts have now been agreed with Recipharm AB and CTC Clinical Trial Consultants AB to respectively produce the test material and to conduct the actual clinical trials.
16 October 2015
Klaria Pharma Holding AB to be listed on Nasdaq Stockholm First North
Klaria Pharma Holding AB has now been approved for registration on Nasdaq Stockholm First North. First day of trading will be the 21st of October. The complete Company Description can be downloaded from klaria.com (http://klaria.com/en/home/).